Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D51VYQ
|
|||
| Drug Name |
514G3
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Staphylococcus infection [ICD-11: 1B5Y; ICD-10: A49.0; ICD-9: 001-139] | Phase 1/2 | [1] | |
| Company |
XBiotech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Staphylococcus IgG binding protein A (Stap-coc SpA) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02357966) A Study of the Safety and Efficacy of 514G3 in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus. U.S. National Institutes of Health. | |||
| REF 2 | A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia. PLoS One. 2018 Jan 24;13(1):e0190537. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.